Cardiac Output Monitoring Managing Intravenous Therapy (COMMIT) to Treat Emergency Department Patients with Sepsis.

"The author reports no conflicts of interest. Since this was an industry sponsored trial, all authors received research funding from Cheetah medical (as described above)."

"This study was sponsored by Cheetah Medical, Tel Aviv, Israel. The study investigators had primary input into the study design, data collection form creation, performed the analysis, and both drafted the primary manuscript and had final editorial decision-making. As the sponsor, Cheetah Medical had also input into the study design, assisted with data collection, and reviewed the final manuscript. They did not dictate journal submission."

"This was a prospective, multicenter, nonblinded randomized-controlled trial that enrolled ED patients at 10 participating centers. Patients meeting entry criteria were randomized (1:1, stratified by site, in permutation blocks of 4 to “Intervention” or “Standard Care” arms). “Intervention” patients were treated with a stroke volume (SV)-guided fluid administration protocol (see Fig. ), whereas “Standard of Care” (SOC) patients received care as dictated by the clinical team. The intervention consisted of up to four fluid bolus cycles, after which routine care was resumed. The study was registered on clinical trials.gov (NCT01484106, registered November 28, 2011), and all patients were enrolled with a written informed consent overseen study-wide by the Beth Israel Deaconess Committee on Clinical investigations, with each institution's human subjects committees approving the study locally. This study was sponsored by Cheetah Medical."